Overview of tumor immunotherapy based on approved drugs
Ziqin Chen,Tiantian Hu,Jing Zhou,Xiaolei Gu,Song Chen,Qing Qi,Ling Wang
DOI: https://doi.org/10.1016/j.lfs.2024.122419
IF: 6.78
2024-03-01
Life Sciences
Abstract:Tumor immunotherapy has become a new hotspot for cancer treatment. Various immunotherapies, such as immune checkpoint inhibitors, oncolytic viruses (OVs), cytokines, and cancer vaccines, have been used to treat tumors. They operate through different mechanisms, along with certain toxicities and side effects. Understanding the mechanisms by which immunotherapy modulates the immune system is essential for improving the efficacy and managing these adverse effects. This article discusses various currently approved cancer immunotherapy mechanisms and related agents approved by the Food and Drug Administration, the European Medicines Agency, and the Medicines and Medical Devices Agency. We also review the latest progress in immune drugs approved by the National Medical Products Administration, including monoclonal antibodies, cytokines, OVs, and chimeric antigen receptor-T cell therapy, to help understand the clinical application of tumor immunotherapy.
pharmacology & pharmacy,medicine, research & experimental